Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Brittney H. Cotta Image

      Brittney H. Cotta, MD

      Department of Urology, Division of Surgery

      In the News

      Colorful illustration of a cut-out of kidneys on a beige background

      What is a nephrectomy? 8 things to know about kidney removal surgery

      Present Title & Affiliation

      Primary Appointment

      Assistant Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Dual/Joint/Adjunct Appointment

      Assistant Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2015Southern Illinois University School of Medicine, Springfield, IL, US, Medicine, Doctor of Medicine (MD)
      2009Bradley University, Peoria, Illinois, US, Chemistry (major), Psychology (minor), Bachelor of Science (BS)

      Postgraduate Training

      2021-2023Research Fellow, Translational Research, University of Michigan, Ann Arbor, MI
      2020-2021Clinical Fellow, Urologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
      2019-2020Chief Resident, Urology, University of California San Diego, San Diego, CA
      2016-2019Resident, Urology, University of California San Diego, San Diego, CA
      2015-2016Intern, General Surgery, University of California San Diego, San Diego, California

      Licenses & Certifications

      2025Diplomate of the American Board of Urology
      2023Texas Medical Board

      Experience & Service

      Intramural Institutional Committee Activities

      Alternate Delegate, Value Analysis Team, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Member, EHR Committee, MD Anderson Cancer Center, 2025 - Present

      Member, Care Team Transformation Steering Committee, MD Anderson Cancer Center, 2025 - Present

      Extramural Institutional Committee Activities

      Member, SUO Kidney Cancer Planning Committee, Society of Urologic Oncology, 2026 - Present

      Member, Research Climate Council Advisory Committee, University of Michigan, 2022 - 2023

      Member, Ethics Committee, University of California San Diego Medical Center, 2019 - 2020

      Member, Resident Physician Council Advisory Committee, University of California San Diego Medical Center, 2016 - 2017

      Member, Human Values and Ethics Committee, Memorial Medical Center, 2014 - 2015

      Student Representative, Year One Curriculum Committee, Southern Illinois University School of Medicine, 2011 - 2012

      Editorial Activities

      Guest Editor, Current Oncology, 2025 - Present

      Honors & Awards

      2025Urologic Oncology Fellowship Teaching Award, MD Anderson Cancer Center
      2024Top 1% of Providers for Patient Experience Nationally, Clinician and Group Consumer Assessment of Healthcare Providers and Systems
      2023Best Reviewer, JU Open Plus
      2022Best Poster Award, American Urological Association Annual Meeting
      2022Best Abstract Award, European Association of Urology Annual Meeting
      2019George W. Kaplan Research Award, UCSD Department of Urology
      2018First Place Resident Essay Contest, San Diego Urologic Society
      2018Earl F. Nation Resident Scholarship, Western Section of the American Urological Association
      2018Residents Bowl Champion, American Urological Association
      2017Residents Bowl Champion, Western Section of the American Urological Association
      2017First Place Resident Research Presentation, San Diego Urologic Society
      2014Best Case Report: Male Sexual Health, Sexual Medicine Society of North America Annual Meeting
      2014Peoria Medical Society Scholarship, Peoria Medical Society
      2014Best Essay: Male Sexual Health, Sexual Medicine Society of North America Annual Meeting
      2012SIU Mentored Professional Enrichment Experience Scholarship, Société Internationale d'Urologie
      2009Cum Laude, Bradley University
      2005Legacy Scholarship, Bradley University
      2005Presidential Scholarship, Bradley University
      2005Honors Program, Bradley University
      2005Valedictorian, Pekin Community High School

      Professional Memberships

      American Association for Cancer Research (AACR)

      2026 - Present

      South Central Section of the American Urological Association

      2023 - Present

      Society of Urologic Oncology

      2019 - Present

      American Urological Association

      2015 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2023. Genomic Biomarkers in Kidney Cancer: Challenges and Future Directions. Invited. University of Michigan Department of Urology Grand Rounds. Ann Arbor, Michigan, US.

      Regional Presentations

      1. 2026. AUA 2026: Kidney Cancer Highlights. Invited. Texas Urological Society Annual Meeting. Austin, TX, US.
      2. 2025. Kidney Cancer Session. Panelist. Annual Meeting of the South Central Section of the AUA, US.
      3. 2025. Challenges Cases in Kidney Cancer. Panelist. University of Texas 3rd Annual Christopher G. Wood Advances in Urologic Oncology Symposium, US.
      4. 2024. AUA 2024: Kidney Cancer Highlights. Invited. Texas Urological Society. Houston, TX, US.
      5. 2024. Radiogenomics in Kidney Cancer: What is the State of the Science?. Invited. University of Texas 2nd Annual Christopher G. Wood Advances in Urologic Oncology Symposium, US.
      6. 2023. Small renal mass management. Invited. UT Dr. Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.

      National Presentations

      1. 2025. Localized Kidney Cancer: How do I Select Patients for Surgery. Panelist. Society of Urologic Oncology Annual Meeting, US.

      International Presentations

      1. 2025. Neoadjuvant Strategies in Locally Advanced Renal Cell Carcinoma. Invited. MD Anderson Cancer Center International GU Cancer Summit and Urologic Endoscopic Surgery Advancement Conference. Kaohsiung, TW.
      2. 2025. Complex Partial Nephrectomy:Surgical Techniques, Outcomes,and Case-Based Discussion. Invited. MD Anderson Cancer Center International GU Cancer Summit and Urologic Endoscopic Surgery Advancement Conference. Kaohsiung, TW.
      Read More
      Less

      Grant & Contract Support

      Date: 2025 - 2030
      Title:Start-Up Funds
      Funding Source:The University of Texas MD Anderson Cancer Center
      Role:PI
      Date: 2021 - 2023
      Title:Ruth L. Kirschstein NRSA Institutional Research Training Grant
      Funding Source:NIH
      Role:Co-PI
      ID:5T32CA180984-06

      Selected Publications

      Peer-Reviewed Articles

      1. Fletcher SA, Cotta BH, Vertosick EA, Liso N, Touijer K, Laudone VP, Eastham JA, Fainberg J, Akin O, Nagar H, Ehdaie B. Concordance Between MRI Findings and Targeted Biopsy for Local Recurrence Following Radical Prostatectomy. Urology, 2026. e-Pub 2026. PMID: 42447965.
      2. Das A, Ellis EE, Tamboli P, Rao P, Venkatesan AM, Li Z, Qiao W, Matin SF, Karam JA, Cotta BH. Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes. Eur Urol Oncol, 2026. e-Pub 2026. PMID: 42055880.
      3. Das, A, Ellis, EE, Tamboli, P, Rao, P, Matin, S, Karam, JA, Cotta, BH. Postoperative surveillance in non clear cell renal cancer. Journal of Clinical Oncology 44:435, 2026. e-Pub 2026.
      4. Cotta B, Nallandhighal S, Monda S, Knuth Z, Triner D, Zhang Y, Wang R, Su F, Kasputis A, Cao X, Udager A, Dhanasekaran SM, Palapattu GS, Mehra R, Cieslik MP, Morgan TM, Salami SS. Molecular profiling of primary versus paired asynchronous metastatic clear cell renal cell carcinoma reveals heterogeneity in tumor immune microenvironment. Sci Rep, 2026. e-Pub 2026. PMID: 41606069.
      5. Cotta BH, Das A. Editorial Comment on "Unraveling Smooth Muscle-Rich Renal Cell Carcinoma: Clinical, Oncological, Genetic, and Pathological Insights". Urology, 2025. e-Pub 2025. PMID: 41418916.
      6. Ghasemzadeh A, Abel EJ, Karam JA, Spiess PE, Peyton CC, Manley BJ, Sirard RB, Robertson N, Ellis EE, Cotta BH, Patel KR, Nicaise E, Jani A, Sexton WJ, Patil D, Allen GO, Matin SF, Master VA, Shapiro DD. Risk Factors for First-Year Recurrence in Patients with Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy. J Urol:101097JU0000000000004705, 2025. e-Pub 2025. PMID: 40763351.
      7. Cotta, BH, Msaouel, P, Karam, JA. Surgical approaches following durable responses to immunotherapy. Kidney Cancer 9, 2025. e-Pub 2025.
      8. Patel P, Nallandhighal S, Scoville D, Cotta B, Knuth Z, Triner D, Tran L, Udager AM, Rao A, Morgan TM, Palapattu GS, Dadhania V, Pitchiaya S, Salami SS. Spatial Transcriptomic Profiling to Characterize the Nature of Peripheral- Versus Transition-zone Prostate Cancer. Eur Urol Focus 11(2):226-234, 2024. e-Pub 2024. PMID: 39613543.
      9. Mehra R, Nallandhighal S, Cotta B, Knuth Z, Su F, Kasputis A, Zhang Y, Wang R, Cao X, Udager AM, Dhanasekaran SM, Cieslik MP, Morgan TM, Salami SS. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma. JCO Precis Oncol 8:e2300565, 2024. e-Pub 2024. PMID: 38810179.
      10. Farha, M, Nallandhighal, S, Vince, R, Cotta, BH, Stangl-Kremser, J, Triner, D, Morgan, TM, Palapattu, GS, Cieślik, M, Vaishampayan, U, Udager, AM, Salami, SS. Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype. Cancers 15(23), 2023. e-Pub 2023. PMID: 38067234.
      11. Toide M, Saito K, Yasuda Y, Tanaka H, Fukuda S, Patil D, Cotta BH, Patel S, Master VA, Derweesh IH, Fujii Y. Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma. Clin Genitourin Cancer 20(4):e276-e282, 2022. e-Pub 2022. PMID: 35410826.
      12. Meagher M, Patil D, Saito K, Javier-Desloges JF, Bradshaw AW, Patel S, Cotta BH, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master VA, Derweesh IH. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma. Urology 163:164-176, 2022. e-Pub 2022. PMID: 34995562.
      13. Cotta BH, Nguyen V, Sur RL, Bechis SK. Opiates prescribed for acute renal colic are associated with prolonged use. World J Urol 39(6):2183-2189, 2021. e-Pub 2021. PMID: 32740804.
      14. Ryan ST, Patel DN, Ghali F, Patel S, Sarkar R, Yim K, Eldefrawy A, Cotta BH, Bradshaw AW, Meagher M, Hamilton ZA, Murphy JD, Derweesh IH. Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer. Minerva Urol Nephrol 73(2):233-244, 2021. e-Pub 2021. PMID: 32748614.
      15. Cotta BH, Meagher M, Patil D, Saito K, Patel S, Patel DN, Miller NS, Dutt R, Keiner C, Bradshaw AW, Wan F, Eldefrawy A, Yasuda Y, Fujii Y, Master VA, Derweesh IH. Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma. BJU Int 127(3):311-317, 2021. e-Pub 2021. PMID: 32772468.
      16. Fukushima H, Saito K, Yasuda Y, Tanaka H, Patil D, Cotta BH, Patel S, Master VA, Derweesh IH, Fujii Y. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery. Clin Genitourin Cancer 18(2):111-116.e1, 2020. e-Pub 2020. PMID: 32001181.
      17. Hamilton ZA, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel DN, Eldefrawy A, Patel S, Cotta BH, Bradshaw AW, Meagher M, Miller NS, Carenzi C, Wan F, Liss MA, McGregor T, Montorsi F, Derweesh IH. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease. Urology 138:60-68, 2020. e-Pub 2020. PMID: 31836465.
      18. Hamilton ZA, Capitanio U, Lane BR, Larcher A, Yim K, Dey S, Cotta BH, Meagher M, Kirmiz S, Bezinque A, Eldefrawy A, Bradshaw AW, Ryan ST, Carenzi C, Wan F, Proudfoot J, Montorsi F, Derweesh IH. Should partial nephrectomy be considered “elective” in patients with stage 2 chronic kidney disease?. World J Urol 37(11):2429-2437, 2019. e-Pub 2019. PMID: 30710156.
      19. Cotta BH, McCammon K, Rourke KF, Rosenstein D, Buckley JC. Training Genitourinary Reconstructive Surgeons. Urology 131:36-39, 2019. e-Pub 2019. PMID: 31136768.
      20. Field CA, Cotta BH, Jimenez J, Lane BR, Yim K, Lee HJ, Ryan ST, Hamilton ZA, Patel S, Wang S, Kane CJ, Dey S, McKay R, Noyes SL, Millard F, Rini BI, Campbell S, Derweesh IH. Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes. Clin Genitourin Cancer 17(3):e505-e512, 2019. e-Pub 2019. PMID: 30808547.
      21. Cotta BH, Welliver Jr RC, Brahmamdam A, Bednarchik CL, Dynda D, Köhler TS. Long-acting liposomal bupivacaine decreases inpatient narcotic requirements in men undergoing penile prosthesis implantation. Turk J Urol 42(4):230-234, 2016. e-Pub 2016. PMID: 27909614.
      22. Cotta BH, Butcher M, Welliver C, McVary KT, Köhler TS. Two Fungal Infections of Inflatable Penile Prostheses in Diabetics. Sex Med 3(4):339-342, 2015. e-Pub 2015. PMID: 26797070.
      23. Hanerhoff BL, Welliver C. Does Early Orchidopexy Improve Fertility?. Transl Androl Urol 3(4):370-376, 2014. e-Pub 2014. PMID: 26816793.
      24. Welliver Jr RC, Hanerhoff B, Henry GD, Köhler TS. Significance of Biofilm for the Prosthetic Surgeon. Current Urology Reports 15(6):411, 2014. e-Pub 2014. PMID: 24740272.

      Review Articles

      1. Cotta BH, Choueiri TK, Cieślik M, Ghatalia P, Mehra R, Morgan TM, Palapattu GS, Shuch B, Vaishampayan U, Van Allen EM, Ari Hakimi A, Salami SS. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. Eur Urol 84(2):166-175, 2023. e-Pub 2023. PMID: 37085424.
      2. Bell H, Cotta BH, Salami SS, Kim HL, Vaishampayan U. 'PROBE'ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Kidney Cancer J 6(1):3-9, 2022. e-Pub 2022.
      3. Berquist SW, Yim K, Ryan ST, Patel S, Eldefrawy A, Cotta BH, Bradshaw AW, Meagher M, Bindayi A, McKay R, Autorino R, Staehler M, Derweesh IH. Systemic therapy in the management of localized and locally advanced renal cell carcinoma. Int J Urol 26(5):532-542, 2019. e-Pub 2019. PMID: 30943578.
      4. Cotta BH, Meagher M, Bradshaw AW, Ryan ST, Rivera-Sanfeliz G, Derweesh IH. Percutaneous renal mass biopsy. Expert Rev Anticancer Ther 19(4):301-308, 2019. e-Pub 2019. PMID: 30656989.
      5. Cotta BH, Buckley JC. Endoscopic Treatment of Urethral Stenosis. Urol Clin North Am 44(1):19-25, 2017. e-Pub 2017. PMID: 27908368.

      Professional Educational Materials

      1. Carlo M, Cotta BH, Mir MC, Msaouel P, Tang C. Renal Neoplasms: Tumor Thrombus and Advanced Disease. American Urological Association, 2026.
      2. Ryan ST, Cotta BH, Parsons JK. Approaching the Patient with Recurrence after Primary Radiation Therapy for Prostate Cancer. American Urological Association, 2019.
      3. Cotta BH, Parsons JK. The Metabolic Syndrome and Benign Urologic Diseases. American Urological Association, 2017.

      Other Articles

      1. Cotta BH Editorial Comment. Journal of Urology 210(6):854, 2023. PMID: 37795824.

      Editorials

      1. Cotta BH, Salami SS. Validation of a 22-Gene Epithelial Mesenchymal Transition Prognostic Signature in Renal Cell Carcinoma. AUA News, 2022.

      Abstracts

      1. Cotta BH, Nallandhighal S, Triner D, Graham N, Mehra R, Cieslik M, Kasputis A, Morgan T, Salami S. Molecular Profiling Reveals Immunosuppressive Tumor Immune Microenvironment in Primary versus Paired Asynchronous Metastatic Clear Cell Renal Cell Carcinoma. Annual Meeting of the American Urological Association 209(4S):e500, 2023. e-Pub 2023.
      2. Cotta BH, Nallandhighal S, Stangl-Kremser J, Pham T, Tosoian JJ, Marchetti K, Berends J, Maruf M, Tomlins SA, Morgan TM, Palapattu GS, Adbulfatah E, Udager AM, Salami S. Validation of a 22-Gene Epithelial-Mesenchymal Transition (EMT) Prognostic Signature in Clear Cell Renal Cell Carcinoma. American Urological Association Annual Meeting 207(5S):e810, 2022. e-Pub 2022.
      3. Nallandhighal S, Scoville D, Tran L, Cotta B, Udager A, Rao A, Palapattu G, Dadhania V, Pitchiaya S, Salami S. Spatial Transcriptomic Profiling of Prostate Cancer Reveals Zone Specific Androgen Receptor Signaling and Immune Infiltration. American Urological Association Annual Meeting 207(5S):e100, 2022. e-Pub 2022.
      4. Cotta B, Nallandhighal S, Hu K, Goldenthal S, Udager A, Salami S. Pan-Cancer Characterization of the Tumor Microenvironment Reveals Stroma and Immune Enriched Subtype with Distinct Molecular, Clinical, and Prognostic Features in Different Genitourinary Cancers. American Urological Association Annual Meeting 207(5S):e34, 2022. e-Pub 2022.
      5. Mehra R, Cieslik M, Kasputis A, Cotta B, Morgan T, Salami S. Whole Transcriptome Sequencing of Clear Cell Renal Cell Carcinoma Reveals a Multigene Expression Prognostic Signature. American Urological Association Annual Meeting 207(5S):e33, 2022. e-Pub 2022.
      6. Cotta BH, Nallandhighal S, Stangl-Kremser J, Pham T, Tosoian JJ, Marchetti K, Berends J, Maruf M, Tomlins SA, Morgan TM, Palapattu GS, Adbulfatah E, Udager AM, Salami S. Validation of a 22-Gene Epithelial-Mesenchymal Transition (EMT) Prognostic Signature in Clear Cell Renal Cell Carcinoma. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 40(6S):377, 2022. e-Pub 2022.
      7. Hamilton Z, Patil D, Saiko K, Bradshaw A, Patel S, Cotta B, Davaro-Comas F, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Elevated C-Reactive Protein is Associated with Postoperative Development of Proteinuria and Subsequent Renal Functional Decline and Mortality. American Urological Association Annual Meeting (cancelled) 203(4S):e257, 2020. e-Pub 2020.
      8. Hamilton Z, Patil D, Saiko K, Bradshaw A, Patel S, Cotta B, Davaro-Comas F, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Survival Outcomes in African Americans in Renal Cell Carcinoma. American Urological Association Annual Meeting (cancelled) 203(4S):e1037-e1038, 2020. e-Pub 2020.
      9. Cotta BH, Saito K, Meagher M, Patil D, Eldefrawy A, Yosuda Y, Bradshaw A, Ryan S, Wan F, Master V, Fujii Y, Derweesh I. Elevated Pre-Operative C-Reactive Protein is Associated with Renal Functional Decline and Non-Cancer Mortality in Surgically Treated Renal Cell Carcinoma. American Urological Association Annual Meeting (cancelled) 203(4S):e758, 2020. e-Pub 2020.
      10. Cotta B, Rose B, Murphy JD, Ryan ST. Association of Salvage Cryoablation with Decreased Utilization of Androgen Deprivation Therapy for Recurrent Prostate Cancer after Radiotherapy. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 38(6S):358, 2020. e-Pub 2020.
      11. Cotta BH, McCammon KA, Rourke K, Rosenstein D, Buckley JC. Training Genitourinary Reconstructive Surgeons. American Urological Association Annual Meeting 131:36-39, 2019. e-Pub 2019.
      12. Lane B, Bradshaw A, Noyes S, Eldefrawy A, Cotta B, Patel S, Bruinius J, Ryan S, Wan F, Derweesh I. Comparison of Renal Functional Outcomes of Active Surveillance and Partial Nephrectomy in the Management of Oncocytoma. American Urological Association Annual Meeting 201(4S):e615, 2019. e-Pub 2019.
      13. Bradshaw A, Capitanio U, Uzzo R, Patil D, Eldefrawy A, Larcher A, Joshi S, Ryan S, Meagher M, Cotta BH, Yee A, Wan F, Montorsi F, Master V, Derweesh I. Proposal for Tripartite Reclassification of cT1 Renal Cell Carcinoma into cT1a (Very Low Risk), cT1b (Low Risk), and cT1c (Intermediate Risk) Substages. American Urological Association Annual Meeting 201(4S):e143, 2019. e-Pub 2019.
      14. Lane B, Larcher A, Patil D, Meagher M, Capitanio U, Noyes S, Eldefrawy A, Cotta BH, Bruinius J, Ryan S, Wan F, Montorsi F, Master V, Derweesh I. Comparison of Renal Functional Outcomes of Partial Nephrectomy vs. Angioembolization in the Treatment of Angiomyolipoma. American Urological Association Annual Meeting 201(4S):e290-e291, 2019. e-Pub 2019.
      15. Cotta BH, Bechis S. Risk Factors for Prolonged Opiate Use in Patients with Acute Nephrolithiasis. American Urological Association Annual Meeting 201(4S):e843-e844, 2019. e-Pub 2019.
      16. Meagher M, Saito K, Patil D, Bindayi A, Eldefrawy A, Ryan S, Cotta B, Yim K, Nasseri R, Hamilton Z, Yasuda Y, Fujii Y, Master V, Derweesh I. Association of Elevated C-Reactive Protein with Oncologic Outcomes in Renal Cell Carcinoma. American Urological Association Annual Meeting 201(4S):e749, 2019. e-Pub 2019.
      17. Cotta BH, Saito K, Meagher M, Patil D, Eldefrawy A, Yosuda Y, Bradshaw A, Ryan S, Anyakora D, Yee A, Alksne J, Wan F, Master V, Fujii Y, Derweesh I. Elevated C-Reactive Protein is Independently Associated with Progressive Renal Functional Decline after Surgery for Renal Cell Carcinoma. American Urological Association Annual Meeting 201(4S):e438-e439, 2019. e-Pub 2019.
      18. Ryan S, Cotta B, Sarkar R, Bradshaw A, Meagher M, Hamilton Z, Murphy J, Derweesh I. Pattern of treatment approaches and outcome of Adrenocortical Carcinoma. American Urological Association Annual Meeting 201(4S):e989, 2019. e-Pub 2019.
      19. Bradshaw A, Uzzo R, Capitanio U, Patil D, Joshi S, Larcher A, Ryan S, Meagher M, Cotta B, Yee A, Wan F, Montorsi F, Master V, Derweesh I. Negative Impact of Positive Margins in Partial Nephrectomy in Stage I Renal Cell Carcinoma. American Urological Association Annual Meeting 201(4S):e832-e833, 2019. e-Pub 2019.
      20. Capitanio U, Pruthi D, Larcher A, Bindayi A, Ryan S, Eldefrawy A, Meagher M, Yim K, Patel S, Cotta B, Bradshaw A, Wan F, McGregor T, Montorsi F, Derweesh I. Dividing Pathologically Upstaged T3a Renal Cell Carcinoma based on Clinical T stage at Presentation is Associated with Improved Alignment of Outcomes. American Urological Association Annual Meeting 201(4S):e142-e143, 2019. e-Pub 2019.
      21. Saito K, Yasuda Y, Tanabe K, Fukuda S, Fukushima H, Yokoyama M, Ishioka J, Matsuoka Y, Patil D, Cotta B, Patel S, Master V, Derweesh I, Fujii Y. Prognostic Significance of C-reactive Protein on Survival in Patients with Non-Metastatic Papillary Renal Cell Carcinoma. American Urological Association Annual Meeting 201(4S):e277, 2019. e-Pub 2019.
      22. Fukushima H, Saito K, Yasuda Y, Tanabe K, Toide M, Fukuda S, Yokoyama M, Ishioka J, Matsuoka Y, Patil D, Cotta B, Patel S, Master V, Derweesh I, Fujii Y. Prognostic Impact of Sex in Non-Metastatic Clear Cell Renal Cell Carcinoma Patients Undergoing Curative Surgery. American Urological Association Annual Meeting 201(4S):e530, 2019. e-Pub 2019.
      23. Cotta BH, Ryan S, Eldefrawy A, Sarkar R, Bradshaw A, Meagher MF, Hamilton Z, Murphy JD, Derweesh I. Does Increasing Time to Surgery Affect Survival in Stage 1 Renal Cell Carcinoma?. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 37(7S), 2019. e-Pub 2019.
      24. Meagher MF, Patil DH, Saito K, Cotta BH, Yasuda Y, Bradshaw A, Eldefrawy A, Ryan S, Nasseri R, Anyakora D, Alksne J, Wan F, Fujii Y, Master V, Derweesh I. Development and Validation of a Novel Scoring Index CART (C-reactive protein, age, race, and tumor size) to Predict Renal Functional Decline Post Partial Nephrectomy. Annual Meeting of the Society of Urologic Oncology 37(7S), 2019. e-Pub 2019.
      25. Hamilton Z, Nseyo U, Cotta BH, Schenker-Ahmed N, Karow D, Kader AK, Kane CJ, Parsons JK. Clinical Utility of MRI/Fusion Biopsy in Prostate Cancer Patients on Active Surveillance. American Urological Association Annual Meeting 197(4):e556, 2017. e-Pub 2017.
      26. Parsons JK, Ross A, Shafei AE, Hatem A, Cotta BH, Tay KJ, Polascik T, Given R, Mouraviev V, Jones JS. Salvage Prostate Cryoablation in Older Men. American Urological Association Annual Meeting 197(4S):e1116-e1117, 2017. e-Pub 2017.
      27. Triner D, Pham T, Nallandhighal S, Cotta BH, Knuth Z, Sun F, Udager A, Dhanasekaran S, Merrill N, Salami SS. Integrative Molecular Profiling of Renal Cell Carcinoma Native Tissue and Patient Derived Organoids Identifies Predictive Markers of Drug Resistance. American Urological Association Annual Meeting.
      28. Cotta BH, Nallandhighal S, Mehra R, Cieslik M, Farha M, Kasputis A, Morgan TM, Salami SS. Characterization of the Tumor Immune Microenvironment between Primary and Paired Asynchronous Metastatic Clear Cell Renal Cell Carcinoma. European Association of Urology Annual Meeting.
      29. Cotta BH, Nallandhighal S, Stangl-Kremser J, Pham T, Tosoian JJ, Marchetti K, Berends J, Maruf M, Tomlins SA, Morgan TM, Palapattu GS, Adbulfatah E, Udager AM, Salami S. Validation of a 22-Gene Epithelial-Mesenchymal Transition (EMT) Prognostic Signature in Clear Cell Renal Cell Carcinoma. European Association of Urology Annual Meeting.
      30. Hanerhoff B, Welliver Jr RC, Brahmamdam A, Bednarchik CL, Dynda D, Köhler TS. Long-Acting Liposomal Bupivacaine Decreases Inpatient Narcotic Requirements in Men Undergoing Penile Prosthesis Implantation. 15th Annual Fall Scientific Meeting of SMSNA.
      31. Sulaver R, Welliver C, Kottwitz M, Frederick L, Hanerhoff B, Dynda D, Koehler T. Scrotoplasty at Time of Penile Implant is at High Risk for Dehiscence in Diabetics. American Urological Association Annual Meeting.
      32. Hamilton Z, Nseyo U, Cotta BH, Schenker-Ahmed N, Karow D, Kader AK, Kane CJ, Parsons JK. Confirmatory MRI-guided Prostate Biopsy Informs Clinical Care in an Active Surveillance Protocol. Annual Meeting of the Society of Urologic Oncology.
      33. King SA, McDonald ML, Fero KE, Cotta BH, Sakamoto K, Goldstein I. A Retrospective Review of Protocol-Based Intralesional Injection Therapy Management of Peyronie's Disease at the La Jolla Veteran's Administration Medical Center (VAMC). 17th Annual Fall Scientific Meeting of SMSNA.
      34. Parsons JK, Ross A, El Shafei A, Hatem A, Cotta BH, Tay KJ, Polascik T, Given R, Mouraviev V, Jones JS. Salvage Prostate Cryoablation in Older Men. European Association of Urology Annual Congress 16(3):e1328-e1329.
      35. Cotta BH, Millard F, Derweesh I, Kader AK, Kane CJ. Histologic Outcomes of Post-Chemotherapy Retroperitoneal Lymph Node Dissection. Western Section of the American Urological Association 93rd Annual Meeting.
      36. Hamilton Z, Nseyo U, Cotta BH, Schenker-Ahmed N, Karow D, Kader AK, Kane CJ, Parsons JK. MPMRI/Fusion-Guided Prostate Biopsy of PIRADS 4 and 5 Lesions Improves the Detection of Clinically Significant Cancer in Patients on Active Surveillance. Western Section of the American Urological Association 93rd Annual Meeting.
      37. Hamilton Z, Haifler M, Krabbe LM, Ryan ST, Reddy M, Berquist S, Clinton TN, Bloch A, Field C, Patel S, Cotta BH, Margulis V, Uzzo R, Derweesh I. Size-focality-invasion in Upper Tract Urothelial Carcinoma. American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium.
      38. Cotta BH, Bechis SK. Opiate Prescribing Patterns and Risk Factors for Prolonged Opiate Use in Patients with Acute Nephrolithiasis. Western Section of the American Urological Association 94th Annual Meeting.
      39. Cotta BH, Field CA, Jimenez J, Lane B, Lee H, Ryan ST, Hamilton Z, Wang S, Kane CJ, Dey S, McKay R, Noyes S, Millard F, Rini B, Campbell SC, Derweesh ID. Neoadjuvant Sunitinib is associated with Improved Oncologic Outcomes for Patients with Tumor Thrombus in Renal Cell Carcinoma. Western Section of the American Urological Association 94th Annual Meeting.
      40. Cotta BH, Patil D, Derweesh I, Nasseri R, Elbakry A, Melnick K, Pearl J, Bindayi A, Bilen MA, Ogan K, Master VA. External Validation of RISK Preoperative Inflammatory Score in Localized Renal Cell Carcinoma. Western Section of the American Urological Association 94th Annual Meeting.
      41. Cotta BH, Ryan S, Eldefrawy A, Sarkar R, Bradshaw A, Meagher MF, Hamilton Z, Murphy JD, Derweesh I. Does Increasing Time to Surgery Affect Survival in Stage 1 Renal Cell Carcinoma?. Annual Meeting of the Society of Urologic Oncology.
      42. Cotta BH, Saito K, Meagher MF, Patil D, Eldefrawy A, Yosuda Y, Bradshaw A, Ryan S, Anyakora D, Yee A, Alksne J, Wan F, Master V, Fujii Y, Derweesh I. Elevated C-Reactive Protein is Independently Associated with Progressive Renal Functional Decline after Surgery for Renal Cell Carcinoma. Annual Meeting of the Society of Urologic Oncology.
      43. Cotta BH, Saito K, Meagher M, Patil D, Eldefrawy A, Yosuda Y, Bradshaw A, Ryan S, Anyakora D, Yee A, Alksne J, Wan F, Master V, Fujii Y, Derweesh I. Elevated C-Reactive Protein is Independently Associated with Progressive Renal Functional Decline after Surgery for Renal Cell Carcinoma. European Association of Urology Annual Meeting.
      44. Korte KE, Hanerhoff B, Campbell DJ. Effects of Threonine on the Morphology of Noble Metal Colloids. Illinois State Academy of Science 100th Annual Meeting.
      45. Hanerhoff B. Memantine and Riluzole Do Not Reverse the Neurotoxic Effects Resulting from Chronic Exposure to Depleted Uranium. Society of Toxicology 51st Annual Meeting.
      46. Hanerhoff B, Myckatyn T. Economic Impact of AlloDerm on Prosthetic Breast Reconstruction. Southern Illinois University School of Medicine MPEE Research Symposium.
      47. Han K, Barbour JR, Kadkhodayan TS, Iorio ML, Hanerhoff B, Myckatyn TM. Analysis of the Deep and Superficial Inferior Epigastric Arteries Using Computed Tomographic Angiography. American Society of Plastic Surgeons Annual Meeting.

      Book Chapters

      1. Ellis EE, Cotta BH, Merrill MM, Karam JA. Postoperative Surveillance Protocols for Renal Cell Carcinoma. In: Renal Cancer: Contemporary Management. 3. Springer Nature, 2025.
      2. Cotta BH, Welliver C, Wynia B. Penile Rehabilitation after Prostate Cancer Treatments. In: Contemporary Treatment of Erectile Dysfunction: A Clinical Guide. 2. Humana Press, 277-288, 2016.

      Web Publications

      1. Cotta BH, Salami SS. AUA 2022: BEST POSTERS Validation of a 22-Gene Epithelial Mesenchymal Transition Prognostic Signature in Renal Cell Carcinoma.
      Read More
      Less

      Patient Reviews


      CV information above last modified August 07, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top